The purpose of this study is to evaluate the effect of escitalopram after 8 weeks of
      treatment in patients with Generalized Anxiety Disorder (GAD), to evaluate proportion of
      patients who respond to escitalopram during the treatment period, and to evaluate safety of
      escitalopram.

Escitalopram in Patients With Generalized Anxiety Disorder

Generalized Anxiety Disorder

The study will be performed in Russia, as an open-label, uncontrolled, one arm trial. The
      patients will receive escitalopram for 8 weeks. Start and maintenance dosages as well as dose
      titration will be left to the investigators' decision (5 to 20 mg/day), in accordance with
      the national Summary of Products Characteristics (SPC).

Escitalopram

Efficacy and Safety of Escitalopram in Patients With Generalized Anxiety Disorder; Open-label, One Arm Postmarketing Study in Russia

The HAMA is a 14-item rating scale designed to assess global anxiety symptoms. Each symptom is rated from 0 (absent) to 4 (severe). The total score of the 14 items ranges from 0 to 56.

The CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).

The SDS comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scale, on which 0 = normal functioning and 10 = severe functional impairment.

Escitalopram in Patients With Generalized Anxiety Disorder

About this trial

Study ID

Status

Type

Phase

Placebo

Accepting

Not accepting

Trial Timing

What is this trial about?

What are the participation requirements?